Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Mar 14;2018(1):5.
doi: 10.21542/gcsp.2018.5.

Individualizing immunosuppression in lung transplantation

Jennifer K McDermott  1   2 , Reda E Girgis  2
Affiliations
Review

Individualizing immunosuppression in lung transplantation

Jennifer K McDermott et al. Glob Cardiol Sci Pract. .

Abstract

Immunosuppression management after lung transplantation continues to evolve, with an increasing number of agents available for use in various combinations allowing for more choice and individualization of immunosuppressive therapy. Therapeutic developments have led to improved outcomes including lower acute rejection rates and improved survival. However, a one size fits all approach for any immunosuppressive strategy may not be best suited to the individual patient and ultimately patient specific factors must be considered when designing the immunosuppressive regimen. Recipient factors including age, race, co-morbidities, immunologic risk, genetic polymorphisms, concomitant and previous pharmacotherapy, and overall immunosuppression burden should be considered. There are several significant drug-drug interactions with select immunosuppressive agents utilized in lung transplant pharmacotherapy that must be considered when choosing and devising a dosing strategy for an individual immunosuppressive agent. Herein, considerations for immunosuppression management in the individual patient will be reviewed.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.. Individual immunosuppressive drugs and sites of action.
Reprinted with permission from: Luis Alonso-Pulpón et al. Heart 2012;98:878-889.
Figure 2.
Figure 2.. Spectrum Health Lung Transplant Immunosuppression Guideline.
See this image and copyright information in PMC

References

    1. Valapour M, Skeans MA, Smith JM, Edwards LB, Cherikh WS, Uccellini K, et al. OPTN/SRTR 2015 Annual Data Report: Lung. American Journal of Transplantation: Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2017;17(Suppl 1):357–424. - PubMed
    1. Yusen RD, Edwards LB, Dipchand AI, Goldfarb SB, Kucheryavaya AY, Levvey BJ, et al. The Registry of the International Society for Heart and Lung Transplantation: Thirty-third Adult Lung and Heart-Lung Transplant Report-2016; Focus Theme: Primary Diagnostic Indications for Transplant. The Journal of Heart and Lung Transplantation: The Official Publication of the International Society for Heart Transplantation. 2016;35(10):1170–1184. - PubMed
    1. Adult lung transplantation statistics. 2016. Available from: http://www.ishlt.org/registries/slides.asp?slides=heartLungRegistry .
    1. Berard JL, Velez RL, Freeman RB, Tsunoda SM. A review of interleukin-2 receptor antagonists in solid organ transplantation. Pharmacotherapy. 1999;19(10):1127–1137. - PubMed
    1. Thymoglobulin® [package insert] Genzyme Corporation; Cambridge, MA: 2017.